

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 March 2022 (31.03.2022)



(10) International Publication Number
WO 2022/063262 A1

(51) International Patent Classification:

C07K 16/22 (2006.01) A61K 39/395 (2006.01)
C07K 16/46 (2006.01) A61P 19/00 (2006.01)
C12N 15/13 (2006.01) A61P 35/00 (2006.01)

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/CN2021/120612

(22) International Filing Date:

26 September 2021 (26.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2020/118387

28 September 2020 (28.09.2020) CN

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: **ANGITIA BIOPHARMACEUTICALS GUANGZHOU LIMITED** [CN/CN]; 2-3F, Unit 02, Building 4, 188 Kaiyuan Avenue, Huangpu District, Guangzhou, Guangdong 510530 (CN).

(72) Inventors: **LIU, Xiaofeng**; 2-3F, Unit 02, Building 4, 188 Kaiyuan Avenue, Huangpu District, Guangzhou, Guangdong 510530 (CN). **LIU, Kunfeng**; 2-3F, Unit 02, Building 4, 188 Kaiyuan Avenue, Huangpu District, Guangzhou, Guangdong 510530 (CN). **YUAN, Baozhi**; 2-3F, Unit 02, Building 4, 188 Kaiyuan Avenue, Huangpu District, Guangzhou, Guangdong 510530 (CN). **LI, Muyu**; 2-3F, Unit 02, Building 4, 188 Kaiyuan Avenue, Huangpu District, Guangzhou, Guangdong 510530 (CN). **KE, Hua Zhu**; 2-3F, Unit 02, Building 4, 188 Kaiyuan Avenue, Huangpu District, Guangzhou, Guangdong 510530 (CN).

(74) Agent: **BEIJING CAIHE LAW FIRM**; Floor 16, Fuhai International Plaza, No. 17, Daliushu Road, Haidian District, Beijing 100081 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: ANTI-SCLEROSTIN CONSTRUCTS AND USES THEREOF

(57) Abstract: The present application provides anti-Sclerostin constructs that bind to Sclerostin (e.g., anti-Sclerostin antibodies, e.g., bispecific anti-Sclerostin antibodies), nucleic acid molecules encoding an amino acid sequence of the anti-Sclerostin, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of preparing the anti-Sclerostin construct, pharmaceutical compositions containing the anti-Sclerostin construct, and methods of using the anti-Sclerostin construct or compositions.

WO 2022/063262 A1